Exhibitors Search

CURSUS BIO

Booth no. E41
Exhibition PARTNERING
Country Korea, South
Address 222 Wangsimni-ro, Seongdong-gu, Seoul, Republic of Korea
Tel (Rep.) 02-2220-4345
E-mail  
Website http://cursusbio.com/

Company Introduction

Cursus Bio is a leading biotech company pioneering innovation in the treatment of obesity and metabolic diseases. We are developing next-generation gene-based obesity therapeutics that overcomes the limitations of existing GLP-1 analogs. By targeting adipocytes directly with a 'First-in-Class' mechanism, we are setting a new therapeutic paradigm. Our core asset, the MicroLock™ patch technology, is a proprietary transdermal drug delivery platform that enables the quantitative delivery of high-dose drugs. It has been validated to achieve efficacy comparable or superior to that of injectables, significantly improving patient access to obesity and metabolic disease treatments through a patient-friendly administration method. Furthermore, we have established a sustainable revenue model through our OEM/ODM business for microneedle cosmetics and pharmaceuticals, leveraging our CGMP-certified manufacturing facilities.

Promotional video

 

Exhibit Item

MicroArray Patch, Cosmetic and Medical Microneedle, Obesity Treatment, Gene Therapy

Exhibit Item Images

  • Product Name : Obesity Gene Therapy, MicroLock™ Patch
    Our obesity gene therapy, is a groundbreaking new drug that overcomes the limitations of existing GLP-1 treatments. By directly targeting adipocytes, it not only effectively reduces body weight but also prevents rebound weight gain. This "first-in-class" mechanism sets a new standard for obesity treatment.
  • Product Name :  
     
  • Product Name :  
     
  • Product Name :  
     
  • Product Name :  
     

Exhibit Description

Cursus Bio's main pipeline, obesity gene therapy, utilizes a differentiated mechanism from existing GLP-1-based treatments by directly targeting adipose cells, the root cause of obesity. It effectively reduces body weight and improves insulin sensitivity. Preclinical studies have demonstrated a 20% reduction in body weight and a weight loss.

Co-Exhibitor or
Partner’s Information

Company Name Country
  
Website http://
Website http://
Website http://
Website http://
Website http://